Lesson 19 of 20

【Capstone lab】 Who can see this fragment?

Redrawing lesson 7's picture from scratch · and who that picture erased

【Capstone lab】 Who can see this fragment?
Choosing a target is also choosing which people.

Last lab. It gathers the previous eighteen lessons into one question.

If you build a therapy against this fragment, how many people can use it?

Three pieces are needed.

What we needWhere fromWhich lesson
Which plate this fragment rides onVDJdb7
What share of people carry that platecited population frequenciesthis one
Whether a different plate really means not seeing it the polymorphism of lessons 8 and 98

Let us stack them in order.

The same skew as lesson 7. This time we attach people to it.
Python Runs in your browser
A person carries two HLA-A copies, so 'people carrying' exceeds the allele frequency.
Python Runs in your browser
This is why TCR therapy starts at A*02:01, and why stopping there is not acceptable.
Python Runs in your browser
Pick plates and stack them. Count for yourself how many it takes to pass half.
Loading…
It shows how coarse a single line of 'A*02 positive' is as a trial criterion.
Python Runs in your browser

So what this one picture says

This is the shape of the table
More than half the records pile onto one plate. Most of the 1,946 fragments are things loaded on A*02:01.
This is the shape of people
About a quarter carry A*02:01 — and that share varies widely by ancestry.
So here is the work
Somebody has to run experiments finding fragments on the less-studied plates. More algorithm will not do it — what is not in the table cannot be computed out of it.

This is where lesson 6's sentence arrives. The skew of this table is the skew of researchers, not of the immune system. And that skew is not merely a statistical matter; it becomes a question of who gets treated.

🤔 Check yourself
A*02:01 alone covers well under half of people. Why is it more than half the table?
🤔 Check yourself
What goes wrong when you multiply and add coverage across several alleles?
🤔 Check yourself
What is the risk of using 'A*02 positive' as a trial criterion?